Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Caroline Gordon, Maame-Boatemaa Amissah-Arthur, Mary Gayed, et al.
Lara D. Veeken (2017) Vol. 57, Iss. 1, pp. e1-e45
Open Access | Times Cited: 306

Showing 1-25 of 306 citing articles:

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
Anand Padmanabhan, Laura Connelly‐Smith, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2019) Vol. 34, Iss. 3, pp. 171-354
Closed Access | Times Cited: 2082
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
Eva Schrezenmeier, Thomas Dörner
Nature Reviews Rheumatology (2020) Vol. 16, Iss. 3, pp. 155-166
Open Access | Times Cited: 1317
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Zhaowei Chen, Jijia Hu, Zongwei Zhang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 868
Novel paradigms in systemic lupus erythematosus
Thomas Dörner, Richard Furie
The Lancet (2019) Vol. 393, Iss. 10188, pp. 2344-2358
Closed Access | Times Cited: 471
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2023) Vol. 38, Iss. 2, pp. 77-278
Closed Access | Times Cited: 275
Clinical practice guideline on pregnancy and renal disease
Kate Wiles, Lucy C. Chappell, Katherine Clark, et al.
BMC Nephrology (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 196
Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options
Eve Smith, Hanna Lythgoe, Angela Midgley, et al.
Clinical Immunology (2019) Vol. 209, pp. 108274-108274
Closed Access | Times Cited: 152
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
Alina Dima, Ciprian Jurcuț, François Chasset, et al.
Therapeutic Advances in Musculoskeletal Disease (2022) Vol. 14
Open Access | Times Cited: 125
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark Russell, Mrinalini Dey, Julia Flint, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. e48-e88
Open Access | Times Cited: 115
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus
Vitor Trindade, Magda Carneiro‐Sampaio, Eloísa Bonfá, et al.
Pediatric Drugs (2021) Vol. 23, Iss. 4, pp. 331-347
Open Access | Times Cited: 112
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees
Iris M. Otani, Heather K. Lehman, Artemio M. Jongco, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 5, pp. 1525-1560
Open Access | Times Cited: 108
New therapeutic strategies in systemic lupus erythematosus management
Mariele Gatto, Margherita Zen, Luca Iaccarino, et al.
Nature Reviews Rheumatology (2018) Vol. 15, Iss. 1, pp. 30-48
Closed Access | Times Cited: 157
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR)
Bernardo A. Pons‐Estel, Eloísa Bonfá, Enrique R. Soriano, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 11, pp. 1549-1557
Open Access | Times Cited: 119
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal
Mohammad Sultan Khuroo
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 3, pp. 106101-106101
Open Access | Times Cited: 118
Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs
Guillermo Ruiz‐Irastorza, George Βertsias
Lara D. Veeken (2020) Vol. 59, Iss. Supplement_5, pp. v69-v81
Open Access | Times Cited: 113
Pulmonary Complications of Systemic Lupus Erythematosus
Jennifer Hannah, David D’Cruz
Seminars in Respiratory and Critical Care Medicine (2019) Vol. 40, Iss. 02, pp. 227-234
Closed Access | Times Cited: 109
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
Roland Derwand, Martin Scholz, Vladimir Zelenko
International Journal of Antimicrobial Agents (2020) Vol. 56, Iss. 6, pp. 106214-106214
Open Access | Times Cited: 102
Systemic lupus erythematosus: state of the art on clinical practice guidelines
Farah Tamirou, Laurent Arnaud, Rosaria Talarico, et al.
RMD Open (2018) Vol. 4, Iss. Suppl 1, pp. e000793-e000793
Open Access | Times Cited: 94
Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
Sabrina Porta, Álvaro Danza, Maira Arias Saavedra, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 9, pp. 2709-2709
Open Access | Times Cited: 84
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Yoshiya Tanaka, Raj Tummala
Modern Rheumatology (2020) Vol. 31, Iss. 1, pp. 1-12
Open Access | Times Cited: 80
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus
Muhammad Shipa, Andrew Embleton-Thirsk, Mariea Parvaz, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 12, pp. 1647-1657
Open Access | Times Cited: 67
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
Richard Furie, Eric F. Morand, Anca Askanase, et al.
Lupus (2021) Vol. 30, Iss. 8, pp. 1254-1263
Closed Access | Times Cited: 64
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions
Dennis Niebel, Luka de Vos, Tanja Fetter, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 4, pp. 521-540
Open Access | Times Cited: 35
Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets
Hannah F. Bradford, Liis Haljasmägi, Madhvi Menon, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 1, pp. 100894-100894
Open Access | Times Cited: 29
Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force
Eve Smith, Amita Aggarwal, Jenny Ainsworth, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 6, pp. 788-798
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top